Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 22
- Registration Number
- NCT00503984
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Azacytidine and Valproic Acid in Patients With Advanced Cancers
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 69
- Registration Number
- NCT00496444
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 16
- Registration Number
- NCT00495547
- Locations
- 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸Hospital la Paz, Madrid, Spain
🇪🇸Hospital Clínic Universitari, Barcelona, Spain
AVIDA The Vidaza® (Azacitidine) Patient Registry
- Conditions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Celgene
- Target Recruit Count
- 479
- Registration Number
- NCT00481273
- Locations
- 🇺🇸
AVIDA Registry Help, Kansas City, Missouri, United States
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2007-03-30
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- The University of New South Wales
- Target Recruit Count
- 2000
- Registration Number
- NCT00454480
- Locations
- 🇬🇧
Queen's Hospital, Burton-upon-Trent, England, United Kingdom
🇬🇧Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom
🇬🇧Hereford Hospitals, Hereford, United Kingdom
A Phase II Study of Maintenance With Azacitidine in MDS Patients
- Conditions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 39
- Registration Number
- NCT00446303
- Locations
- 🇫🇷
CHU de Caen, Caen, France
🇫🇷CHU d'Amiens, Amiens, France
🇫🇷Hopital d'Instruction des Armées Percy, Clamart, France
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT00443261
- Locations
- 🇺🇸
Kansas City VA Medical Center, Kansas City, Missouri, United States
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS
- Conditions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2018-08-07
- Target Recruit Count
- 62
- Registration Number
- NCT00439673
- Locations
- 🇮🇹
Ospedale Reg. A di Summa, Brindisi, Italy
🇮🇹Ospedale A. Businco, Cagliari, Italy
🇮🇹Università degli studi di Roma La Cattolica, Roma, Italy
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 7
- Registration Number
- NCT00412919
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00413478
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.